Bausch Health, Canada, has advised that in the fall this year, Emerade™ epinephrine auto-injectors will be available in Canada.
We have been strongly advocating over the last two years to ensure there is always affordable access to life-saving medication by having a minimum of two epinephrine auto-injector suppliers in Canada long-term. With Emerade, there will now three suppliers to choose from, giving Canadians more choice and the option to select the device best suited for them.
As you may not be familiar with Emerade, we have put together some quick Q/As below.
Q. What is Emerade?
Emerade is an epinephrine auto-injector used to treat anaphylaxis.
Q. What dosages are available in Canada?
There will be two doses available with the Emerade device: 0.3 mg and 0.5 mg. In Canada, the 0.5 mg is a new dose option, please speak to your doctor to determine which dosage strength is best for you.
Q. What about a 0.15 mg dose?
Emerade will not be launching with a 0.15 mg dosage in Canada at this time.
Q. Will the price be the same as the other devices in the market?
Bausch Health, Canada has indicated that the price will be similar to the cost of the other devices available in Canada.
We will let you know when the device launches later this year and how you can access it when it does. In the meantime, visit emerade.ca for more information.Tags: auto-injector, Emerade, Epinephrine